BRPI1016109A2 - "composto, composição farmacêutica, e, processo para preparar um composto" - Google Patents
"composto, composição farmacêutica, e, processo para preparar um composto"Info
- Publication number
- BRPI1016109A2 BRPI1016109A2 BRPI1016109A BRPI1016109A BRPI1016109A2 BR PI1016109 A2 BRPI1016109 A2 BR PI1016109A2 BR PI1016109 A BRPI1016109 A BR PI1016109A BR PI1016109 A BRPI1016109 A BR PI1016109A BR PI1016109 A2 BRPI1016109 A2 BR PI1016109A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21853909P | 2009-06-19 | 2009-06-19 | |
PCT/GB2010/051003 WO2010146395A1 (en) | 2009-06-19 | 2010-06-17 | Pyrazine carboxamides as inhibitors of dgat1 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1016109A2 true BRPI1016109A2 (pt) | 2016-05-17 |
Family
ID=42357808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1016109A BRPI1016109A2 (pt) | 2009-06-19 | 2010-06-17 | "composto, composição farmacêutica, e, processo para preparar um composto" |
Country Status (14)
Country | Link |
---|---|
US (2) | US8188092B2 (pt) |
EP (1) | EP2443096A1 (pt) |
JP (1) | JP2012530122A (pt) |
KR (1) | KR20120037939A (pt) |
CN (1) | CN102498103A (pt) |
AR (1) | AR077140A1 (pt) |
AU (1) | AU2010261499A1 (pt) |
BR (1) | BRPI1016109A2 (pt) |
CA (1) | CA2764013A1 (pt) |
MX (1) | MX2011014018A (pt) |
RU (1) | RU2011152517A (pt) |
TW (1) | TW201103895A (pt) |
UY (1) | UY32716A (pt) |
WO (1) | WO2010146395A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE500251T1 (de) * | 2006-06-08 | 2011-03-15 | Astrazeneca Ab | Benzimidazole und ihre verwendung zur behandlung von diabetes |
WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
EP2684879A1 (en) | 2012-07-09 | 2014-01-15 | Basf Se | Substituted mesoionic compounds for combating animal pests |
JP6099753B2 (ja) | 2012-10-03 | 2017-03-22 | アドビナス セラピューティクス リミテッド | スピロ環化合物、その組成物及びその医薬応用 |
TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Flap調節劑 |
US9745328B2 (en) | 2013-02-04 | 2017-08-29 | Janssen Pharmaceutica Nv | Flap modulators |
CN103467392B (zh) * | 2013-10-09 | 2016-08-17 | 重庆工商大学 | 一种多卤代吡嗪甲酰胺衍生物及其盐类、制备方法和用途 |
CN103880757B (zh) * | 2014-04-15 | 2016-02-24 | 上海毕得医药科技有限公司 | 一种5-羟基嘧啶-2-羧酸的合成方法 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3245989A (en) | 1962-12-15 | 1966-04-12 | Acraf | 3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles |
US4983731A (en) | 1989-03-17 | 1991-01-08 | Nebraska Department Of Economic Development | Separation and purification of sugar esters |
IL109431A (en) | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
US5491172A (en) | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
US20030167483A1 (en) | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
AU2856499A (en) | 1999-03-25 | 2000-10-16 | Kitasato Institute, The | Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same |
TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
CA2369967A1 (en) | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
JP2002284741A (ja) | 2001-03-23 | 2002-10-03 | Kitasato Inst:The | ローズリピン誘導体 |
DE10223273A1 (de) | 2002-05-24 | 2003-12-04 | Aventis Pharma Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
ATE347890T1 (de) | 2001-08-31 | 2007-01-15 | Sanofi Aventis Deutschland | Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar- aktivatoren |
US20090286791A1 (en) | 2001-11-27 | 2009-11-19 | Takeda Pharmaceutical Company Limited | Amide Compounds |
FR2840301B1 (fr) | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
WO2003105209A1 (ja) * | 2002-06-06 | 2003-12-18 | 関西ティー・エル・オー株式会社 | 太陽電池用多結晶シリコン基板の製造方法 |
US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
BR0312697A (pt) | 2002-07-12 | 2005-04-26 | Aventis Pharma Gmbh | Benzoiluréias substituìdas heterociclicamente, processo para a sua preparação e sua aplicação como medicamento |
JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Dgat阻害剤 |
CA2495903A1 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
US7189712B2 (en) | 2002-10-10 | 2007-03-13 | Smithkline Beecham Corporation | 1,3-Oxazole compounds for the treatment of cancer |
NZ539952A (en) | 2002-11-22 | 2008-05-30 | Japan Tobacco Inc | Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X |
ES2552247T3 (es) | 2003-01-08 | 2015-11-26 | The University Of Washington | Agentes antibacterianos |
JP4847314B2 (ja) | 2003-04-07 | 2011-12-28 | コーティカル・ピーティーワイ・リミテッド | 炎症性疾患を治療するための新規な方法 |
AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
US7300932B2 (en) | 2003-08-07 | 2007-11-27 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
US7732442B2 (en) | 2003-09-05 | 2010-06-08 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
US20050143464A1 (en) | 2003-09-22 | 2005-06-30 | Use-Techno Corporation | Insulin secretion potentiator |
EP2264030A1 (en) | 2003-10-17 | 2010-12-22 | Incyte Corporation | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
GB0325192D0 (en) | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
JP4820299B2 (ja) | 2003-11-11 | 2011-11-24 | ザ スキニー ドリンク カンパニー | 肥満、心臓血管疾患及び冠状動脈疾患の予防及び治療のための組成物 |
JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
WO2005072740A2 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
EP1764360A4 (en) | 2004-07-02 | 2010-08-11 | Sankyo Co | UREA DERIVATIVE |
WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
KR20070063546A (ko) | 2004-10-15 | 2007-06-19 | 바이엘 파마슈티칼스 코포레이션 | 비만증 치료를 위한 비페닐-4-일-카르보닐아미노산유도체의 제조법 및 용도 |
WO2006054370A1 (en) | 2004-11-16 | 2006-05-26 | Use-Techno Corporation | Gluconeogenesis inhibiting agent |
KR20070087096A (ko) | 2004-12-14 | 2007-08-27 | 아스트라제네카 아베 | Dgat 억제제로서의 옥사디아졸 유도체 |
EP1845081A4 (en) | 2005-02-01 | 2009-03-25 | Takeda Pharmaceutical | amide |
JP2008529983A (ja) | 2005-02-07 | 2008-08-07 | エフ.ホフマン−ラ ロシュ アーゲー | ジアシルグリセロールアシルトランスフェラーゼ(dgat)の阻害剤 |
KR20080000652A (ko) | 2005-04-19 | 2008-01-02 | 바이엘 파마슈티칼스 코포레이션 | 아릴 알킬산 유도체 및 그의 용도 |
ES2331535T3 (es) | 2005-05-10 | 2010-01-07 | Via Pharmaceuticals, Inc. | Inhibidores de diacilglicerol aciltransferasa. |
KR20080015113A (ko) | 2005-06-11 | 2008-02-18 | 아스트라제네카 아베 | Dgat 억제제로서의 옥사디아졸 유도체 |
WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
CA2617055A1 (en) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity |
JP2007131584A (ja) | 2005-11-11 | 2007-05-31 | Sankyo Co Ltd | 新規ベンゾオキサゾール誘導体 |
EP1963313B1 (en) | 2005-11-28 | 2012-11-14 | Madrigal Pharmaceuticals, Inc. | Inhibitors of diacylglycerol acyltransferase (dgat) |
JP2007191471A (ja) | 2005-12-21 | 2007-08-02 | Sankyo Co Ltd | ウレア誘導体を含有する医薬 |
EP1966221A1 (en) | 2005-12-22 | 2008-09-10 | AstraZeneca AB | Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors |
WO2007074753A1 (ja) | 2005-12-27 | 2007-07-05 | Daiichi Sankyo Company, Limited | 置換されたウレア誘導体を含有する医薬 |
ATE529405T1 (de) | 2006-03-31 | 2011-11-15 | Novartis Ag | (4-(4-ä6-(trifluoromethyl-pyridin-3-ylamino)-n- enthaltend-heteroarylü-phenyl)-cyclohexyl)- essigsäure-derivate und ihre pharmazeutische anwendungen |
JP5265521B2 (ja) | 2006-04-21 | 2013-08-14 | イーライ リリー アンド カンパニー | 11−β−ヒドロキシステロイドデヒドロゲナーゼ1阻害剤としてのビフェニルアミドラクタム誘導体 |
US20080015227A1 (en) | 2006-05-19 | 2008-01-17 | Kym Philip R | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
US20080064717A1 (en) | 2006-05-19 | 2008-03-13 | Rajesh Iyengar | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
CA2651710A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase |
WO2007138304A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
US20090209602A1 (en) | 2006-06-06 | 2009-08-20 | Roger John Butlin | Chemical compounds |
ATE500251T1 (de) | 2006-06-08 | 2011-03-15 | Astrazeneca Ab | Benzimidazole und ihre verwendung zur behandlung von diabetes |
GB0611507D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
GB0611506D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
GB0611552D0 (en) | 2006-06-12 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
WO2008011130A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
US7569590B2 (en) | 2006-09-19 | 2009-08-04 | Bristol-Myers Squibb Company | Use of thianecarboxamides as dgat inhibitors |
KR100795462B1 (ko) | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
KR100811100B1 (ko) | 2006-09-27 | 2008-03-06 | 한국생명공학연구원 | 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물 |
WO2008040651A1 (en) | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents |
PE20080888A1 (es) | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
CA2668744C (en) | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
MX2009005691A (es) | 2006-11-29 | 2009-08-07 | Abbott Lab | Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i. |
AU2007333234A1 (en) | 2006-12-11 | 2008-06-19 | Novartis Ag | Method of preventing or treating myocardial ischemia |
US8242139B2 (en) | 2007-04-30 | 2012-08-14 | Abbott Laboratories | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
US8058299B2 (en) | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
CA2695434A1 (en) | 2007-08-17 | 2009-02-26 | Astrazeneca Ab | Chemical compounds 979 |
CA2707660A1 (en) * | 2007-12-20 | 2009-07-02 | Astrazeneca Ab | Carbamoyl compounds as dgat1 inhibitors 190 |
JP2010132590A (ja) | 2008-12-03 | 2010-06-17 | Astellas Pharma Inc | オキサジアゾール化合物 |
EP2379516A1 (en) | 2008-12-19 | 2011-10-26 | AstraZeneca AB | 1,3,4-oxadiazole derivatives and their uses to treat diabetes |
-
2010
- 2010-06-17 JP JP2012515565A patent/JP2012530122A/ja active Pending
- 2010-06-17 CN CN201080036012XA patent/CN102498103A/zh active Pending
- 2010-06-17 BR BRPI1016109A patent/BRPI1016109A2/pt not_active Application Discontinuation
- 2010-06-17 CA CA2764013A patent/CA2764013A1/en not_active Abandoned
- 2010-06-17 KR KR1020127001363A patent/KR20120037939A/ko not_active Application Discontinuation
- 2010-06-17 WO PCT/GB2010/051003 patent/WO2010146395A1/en active Application Filing
- 2010-06-17 RU RU2011152517/04A patent/RU2011152517A/ru unknown
- 2010-06-17 AU AU2010261499A patent/AU2010261499A1/en not_active Abandoned
- 2010-06-17 EP EP10725494A patent/EP2443096A1/en not_active Withdrawn
- 2010-06-17 UY UY0001032716A patent/UY32716A/es unknown
- 2010-06-17 TW TW099119725A patent/TW201103895A/zh unknown
- 2010-06-17 MX MX2011014018A patent/MX2011014018A/es not_active Application Discontinuation
- 2010-06-18 AR ARP100102161A patent/AR077140A1/es unknown
- 2010-06-18 US US12/818,187 patent/US8188092B2/en not_active Expired - Fee Related
-
2012
- 2012-04-25 US US13/455,275 patent/US20120289520A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW201103895A (en) | 2011-02-01 |
US20120289520A1 (en) | 2012-11-15 |
EP2443096A1 (en) | 2012-04-25 |
US20100324068A1 (en) | 2010-12-23 |
RU2011152517A (ru) | 2013-07-27 |
KR20120037939A (ko) | 2012-04-20 |
CN102498103A (zh) | 2012-06-13 |
CA2764013A1 (en) | 2010-12-23 |
MX2011014018A (es) | 2012-02-22 |
US8188092B2 (en) | 2012-05-29 |
AU2010261499A1 (en) | 2012-01-12 |
JP2012530122A (ja) | 2012-11-29 |
WO2010146395A1 (en) | 2010-12-23 |
AR077140A1 (es) | 2011-08-03 |
UY32716A (es) | 2011-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
BRPI1006162A2 (pt) | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". | |
BRPI0909691A2 (pt) | Composto, método para preparar um composto, e, composição farmacêutica | |
BRPI0905717A2 (pt) | Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica | |
BRPI0910734A2 (pt) | composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo. | |
BRPI0811712A2 (pt) | "composto, processo de preparação de um composto e composição farmacéutica". | |
BRPI0821676A2 (pt) | Composto, composição farmacêutica, e, processo para a preparação dos compostos. | |
BR112013008008A2 (pt) | composto, composição farmacêutica e processo para preparar um composto | |
BRPI0814821A2 (pt) | Composto, composição farmacêutica, e, processo para preparar um composto | |
BR112012016201A2 (pt) | ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto'' | |
BRPI0815784A2 (pt) | Processo para a preparação de 1,2-propanodiol | |
BRPI1011888A2 (pt) | processo para preparar um composto, e, composição. | |
BRPI1014547A2 (pt) | composto, e, processo para preparar um composto. | |
BRPI0905847A2 (pt) | "composição farmacêutica injetável e processo para preparar a composição" | |
BRPI1010128A2 (pt) | "processo para a fabricação do 2,3,3,3 - tetrafluropropeno" | |
BRPI1010933A2 (pt) | processo para a preparação de um pó, e, composto | |
BRPI1007161A2 (pt) | composição farmacêutica oral, e processo para preparar uma composição | |
BRPI1016109A2 (pt) | "composto, composição farmacêutica, e, processo para preparar um composto" | |
BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. | |
BRPI0911897A2 (pt) | Processo para a preparação de compostos, e, composto | |
BRPI0905790A2 (pt) | 'micropartícula, método para a fabricação de micropartícula e preparação farmacêutica | |
BRPI0813772A2 (pt) | Composto, processo para a preparação de um composto, e, conjugado | |
BRPI1014691A2 (pt) | Composto, e, processo para a preparação de um composto. | |
BRPI0817721A2 (pt) | Composto, composição farmacêutica, método de tratamento, e, processo para preparação de um composto | |
BRPI1007654A2 (pt) | composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |